This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Movement Disorders  • Parkinson Disease/ Parkinsonian Disorders  • Alert me on articles by topic

Matthew B. Stern, MD

Arch Neurol. 2004;61:1969-1971.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Physicians treating Parkinson disease (PD) today are focused as much on minimizing the long-term consequences of PD as on immediate control of symptoms. The concept of "modifying" the natural history of a neurodegenerative disease has evolved because of the limitations of purely symptomatic therapies, the inexorable progression of disease, and a research initiative to understand the basic mechanisms of disease and develop appropriate ways to slow or halt neurodegeneration. Modifying the course of PD represents a spectrum of interventions that begins with therapies that treat the motor and nonmotor symptoms and reduce morbidity, mortality, and treatment-related complications and ends with interventions that are aimed at the underlying disease process, so called neuroprotective therapies. Dopamine agonists (DAs) have been part of PD therapy for many years, yet have only been recently studied for their potential to modify the course of PD. There is now overwhelming evidence that . . . [Full Text of this Article]

LEVODOPA


DAs IN EARLY PD

DAs AND NEUROPROTECTION

AUTHOR INFORMATION
Author Affiliation: Penn Neurologic Institute, Philadelphia, Pa.

RELATED ARTICLES

Initial Treatment of Parkinson Disease: Levodopa or Dopamine Agonists
William J. Weiner
Arch Neurol. 2004;61(12):1966-1969.
EXTRACT | FULL TEXT  

Initial Parkinson Disease Therapy: Levodopa, Dopamine Agonists, or Both?
E. S. Roach
Arch Neurol. 2004;61(12):1972-1973.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Both Postsynaptic and Presynaptic Dysfunction Contribute to Parkinson Disease: Any Mechanism Will Not Do
Roach
Arch Neurol 2007;64:143-143.
FULL TEXT  

Dopamine D3 receptor agonist delivery to a model of Parkinson's disease restores the nigrostriatal pathway and improves locomotor behavior.
Van Kampen and Eckman
J. Neurosci. 2006;26:7272-7280.
ABSTRACT | FULL TEXT  

Initial Parkinson Disease Therapy: Levodopa, Dopamine Agonists, or Both?
Roach
Arch Neurol 2004;61:1972-1973.
FULL TEXT